ADMA Biologics(ADMA) ZACKS·2025-01-22 23:56Core Viewpoint - Adma Biologics is experiencing fluctuations in stock performance, with a recent increase in share price, but a decline over the past month, while upcoming financial results are anticipated to show significant year-over-year growth in earnings and revenue [1][2]. Group 1: Stock Performance - Adma Biologics shares closed at 0.15 per share, indicating a year-over-year growth of 275% [2] - Revenue is forecasted to be $112.2 million, representing a 51.83% increase compared to the same quarter last year [2] Group 3: Analyst Projections - Recent shifts in analyst projections for Adma Biologics are important for investors, as positive changes indicate optimism regarding the company's business and profitability [3] - The Zacks Rank system, which incorporates these estimate changes, suggests a correlation between estimate adjustments and stock price performance [4] Group 4: Zacks Rank and Valuation - Adma Biologics currently holds a Zacks Rank of 3 (Hold), with a consensus EPS projection that has decreased by 11.61% in the past 30 days [5] - The company has a Forward P/E ratio of 23.59, which is higher than the industry average of 21.95, indicating it is trading at a premium [6] Group 5: Industry Context - The Medical - Biomedical and Genetics industry, to which Adma Biologics belongs, has a Zacks Industry Rank of 72, placing it in the top 29% of over 250 industries [6] - The Zacks Industry Rank assesses the strength of industry groups, with top-rated industries outperforming lower-rated ones by a factor of 2 to 1 [7]